Nasdaq · Healthcare

Vir Biotechnology, Inc. (VIR)

As-reported financials and recent SEC filings for Vir Biotechnology, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$68.6M

Net income

$-438.0M

Net margin

—

Diluted EPS

$-3.16

ROE

-57.2%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$68.6M	$74.2M	$86.2M	$1.62B	$1.10B
Gross profit	—	—	—	$1.47B	—
Operating income	$-479.3M	$-587.2M	$-684.3M	$833.1M	$420.8M
Net income	$-438.0M	$-522.0M	$-615.1M	$515.8M	$528.6M
Diluted EPS	$-3.16	$-3.83	$-4.59	$3.83	$3.96

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

1442026-06-29

42026-06-10

32026-06-10

8-K2026-06-10

42026-06-02

42026-06-02

1442026-06-01

1442026-06-01

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on VIR

Search Vir Biotechnology, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.